Bioventures Cayman Ltd Hbm Net Worth

The estimated Net Worth of Bioventures Cayman Ltd Hbm is at least $114 Million dollars as of 12 September 2017. Bioventures Hbm owns over 36,608 units of PTC Therapeutics Inc stock worth over $75,322,311 and over the last 14 years Bioventures sold PTCT stock worth over $38,636,391.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Bioventures Hbm PTCT stock SEC Form 4 insiders trading

Bioventures has made over 20 trades of the PTC Therapeutics Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently Bioventures sold 36,608 units of PTCT stock worth $313,364 on 12 September 2017.

The largest trade Bioventures's ever made was selling 909,100 units of PTC Therapeutics Inc stock on 11 March 2013 worth over $25,463,891. On average, Bioventures trades about 121,793 units every 101 days since 2011. As of 12 September 2017 Bioventures still owns at least 2,334,128 units of PTC Therapeutics Inc stock.

You can see the complete history of Bioventures Hbm stock trades at the bottom of the page.

What's Bioventures Hbm's mailing address?

Bioventures's mailing address filed with the SEC is CENTENNIAL TOWERS, 3RD FLOOR, 2454 WEST BAY ROAD, GRAND CAYMAN, CAYMAN ISLANDS, , .

Insiders trading at PTC Therapeutics Inc

Over the last 12 years, insiders at PTC Therapeutics Inc have traded over $50,602,930 worth of PTC Therapeutics Inc stock and bought 3,730,934 units worth $57,374,337 . The most active insiders traders include Suisse/ Credit, Adam Koppel, and Bioventures Cayman Ltd Hbm. On average, PTC Therapeutics Inc executives and independent directors trade stock every 16 days with the average trade being worth of $888,748. The most recent stock trade was executed by Pierre Gravier on 16 July 2024, trading 2,269 units of PTCT stock currently worth $77,191.

What does PTC Therapeutics Inc do?

ptc is biopharmaceutical company focused on the discovery and development of orally-administered, proprietary small molecule drugs that target post-transcriptional control processes. while ptc’s discovery programs are directed at targets in multiple therapeutic areas, ptc is focusing particularly on the development and commercialization of treatments for orphan and ultra-orphan disorders. post-transcriptional control processes regulate the rate and timing of protein production and are essential to proper cellular function. ptc’s internally-discovered pipeline addresses multiple therapeutic areas, including neuromuscular disorders, oncology and infectious diseases. for more information on the company, please visit our website www.ptcbio.com.

Complete history of Bioventures Hbm stock trades at Nabriva Therapeutics Plc, Pacira BioSciences Inc, Paratek Pharmaceuticals, and PTC Therapeutics Inc

PTC Therapeutics Inc executives and stock owners

PTC Therapeutics Inc executives and other stock owners filed with the SEC include:

• Stuart Peltz,
  Chief Executive Officer, Director
• Neil Almstead,
  Chief Technical Operations Officer
• Mark Boulding,
  Executive Vice President, Chief Legal Officer
• Emily Hill,
  Principal Financial Officer, Treasurer
• Dr. Stuart W. Peltz,
  Co-Founder, CEO & Exec. Director
• Christine Utter,
  Senior Vice President - Finance, Chief Accounting Officer
• Mark Elliott Boulding,
  Exec. VP & Chief Legal Officer
• Dr. Neil Almstead,
  Chief Technical Operations Officer
• Michael Schmertzler,
  Independent Chairman of the Board
• Allan Jacobson,
  Independent Director
• Emma Reeve,
  Independent Director
• David Southwell,
  Independent Director
• Dawn Svoronos,
  Independent Director
• Glenn Steele,
  Independent Director
• Jerome Zeldis,
  Independent Director
• Stephanie Okey,
  Independent Director
• Dr. Allan Steven Jacobson,
  Independent Co-Founder, Chairman of Scientific Advisory Board & Director
• Eric Pauwels,
  Chief Business Officer
• Matthew Klein,
  Chief Development Officer
• Jane Baj,
  VP of Corp. Communications
• Alex Kane,
  Investor Relations Officer
• Ellen Welch Ph.D.,
  Chief Scientific Officer
• Christine Utter,
  Sr. VP, Chief Accounting Officer & Head of People Services
• Adam Koppel,
  Director
• Cameron Geoffrey Mc Donough,
  Director
• Tuyen Ong,
  Chief Medical Officer
• Marcio Souza,
  Chief Operating Officer
• Pharma Holdings Ii, Llc Com...,
  10% owner
• Mark Rothera,
  Chief Commercial Officer
• Ronald C Jr Renaud,
  Director
• Suisse/ Credit,
  
• Claudia De Oliveira Ribeiro...,
  President
• Bioventures Cayman Ltd Hbm,
  10% owner
• Robert J. Spiegel,
  Chief Medical Officer
• Richard Aldrich,
  Director
• Ventures Inc.Vulcan Capital...,
  
• Shane William Charles Kovacs,
  EVP, CFO & Head of Corp Dev
• Axel Bolte,
  Director
• Michael L Kranda,
  Director
• Pierre Gravier,
  CHIEF FINANCIAL OFFICER
• Mary L. Smith,
  
• William F. Jr. Bell,
  
• Alethia Young,
  
• Lee Scott Golden,
  EVP & CHIEF MEDICAL OFFICER